Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations

Simply Wall St.11-10

Aligos Therapeutics (NASDAQ:ALGS) Third Quarter 2024 Results Key Financial Results Net loss: US$19.3m (loss widened by 6.8% from 3Q 2023). NasdaqCM:ALGS Earnings and Revenue History November ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482266827?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","is_english":true,"pubTime":"2024-11-10 20:51","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2482266827","market":"us","top_or_hot":-1,"title":"Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations","media":"Simply Wall St.","content":"<div>\n<p>Aligos Therapeutics (NASDAQ:ALGS) Third Quarter 2024 Results\nKey Financial Results\n\nNet loss: US$19.3m (loss widened by 6.8% from 3Q 2023).\n\n\n\n\n  NasdaqCM:ALGS Earnings and Revenue History November ...</p>\n\n<a href=\"https://finance.yahoo.com/news/aligos-therapeutics-third-quarter-2024-125141067.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-10 20:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/aligos-therapeutics-third-quarter-2024-125141067.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aligos Therapeutics (NASDAQ:ALGS) Third Quarter 2024 Results\nKey Financial Results\n\nNet loss: US$19.3m (loss widened by 6.8% from 3Q 2023).\n\n\n\n\n  NasdaqCM:ALGS Earnings and Revenue History November ...</p>\n\n<a href=\"https://finance.yahoo.com/news/aligos-therapeutics-third-quarter-2024-125141067.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://finance.yahoo.com/news/aligos-therapeutics-third-quarter-2024-125141067.html","article_id":"2482266827","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482266827","pubTimestamp":1731243101,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"NasdaqCM:ALGS Earnings and Revenue History November 10th 2024. All figures shown in the chart above are for the trailing 12 month  period. Looking ahead, revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.The company's shares are up 6.7% from a week ago.We should say that we've discovered 5 warning signs for Aligos Therapeutics (3 are potentially serious!) that you should be aware of before investing here.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","ALGS":"Aligos Therapeutics, Inc."},"translate_title":"Aligos Therapeutics 2024年第三季度收益：收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALGS":1,"LENZ":1},"content_text":"Aligos Therapeutics (NASDAQ:ALGS) Third Quarter 2024 Results\nKey Financial Results\n\nNet loss: US$19.3m (loss widened by 6.8% from 3Q 2023).\n\n\n\n\n  NasdaqCM:ALGS Earnings and Revenue History November 10th 2024\n \n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\nAligos Therapeutics Revenues Beat Expectations\n Revenue exceeded analyst estimates significantly. \n Looking ahead, revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. \nPerformance of the American Biotechs industry.\n The company's shares are up 6.7% from a week ago. \nRisk Analysis\n We should say that we've discovered 5 warning signs for Aligos Therapeutics (3 are potentially serious!) that you should be aware of before investing here. \nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482266827"}